Boris Bastian

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8060483/publications.pdf

Version: 2024-02-01

201 papers	30,849 citations	7672 79 h-index	5347 170 g-index
225 all docs	225 docs citations	225 times ranked	29775 citing authors

#	Article	IF	Citations
1	Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes. Genome Medicine, 2022, 14, .	3.6	13
2	Iris and Ciliary Body Melanocytomas Are Defined by Solitary GNAQ Mutation Without Additional Oncogenic Alterations. Ophthalmology, 2022, 129, 1429-1439.	2.5	2
3	Functional characterization of uveal melanoma oncogenes. Oncogene, 2021, 40, 806-820.	2.6	39
4	Fusion partners of NTRK3 affect subcellular localization of the fusion kinase and cytomorphology of melanocytes. Modern Pathology, 2021, 34, 735-747.	2.9	20
5	Multiple desmoplastic Spitz nevi with BRAF fusions in a patient with ring chromosome 7 syndrome. Pigment Cell and Melanoma Research, 2021, 34, 987-993.	1.5	9
6	Melanoma pathology: new approaches and classification*. British Journal of Dermatology, 2021, 185, 282-293.	1.4	25
7	Evaluation of Crizotinib Treatment in a Patient With Unresectable <i>GOPC-ROS1</i> Fusion Agminated Spitz Nevi. JAMA Dermatology, 2021, 157, 836-841.	2.0	9
8	MicroRNA Ratios Distinguish Melanomas fromÂNevi. Journal of Investigative Dermatology, 2020, 140, 164-173.e7.	0.3	32
9	Co-occurring Alterations in the RASâ€"MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clinical Cancer Research, 2020, 26, 439-449.	3.2	64
10	Melanoma to Vitiligo: The Melanocyte in Biology & Medicineâ€"Joint Montagna Symposium on the Biology of Skin/PanAmerican Society for Pigment Cell Research Annual Meeting. Journal of Investigative Dermatology, 2020, 140, 269-274.	0.3	2
11	Melanocytic tumors with MAP3K8 fusions: report of 33 cases with morphological-genetic correlations. Modern Pathology, 2020, 33, 846-857.	2.9	38
12	Next-Generation Sequencing of Retinoblastoma Identifies Pathogenic Alterations beyond RB1 Inactivation That Correlate with Aggressive Histopathologic Features. Ophthalmology, 2020, 127, 804-813.	2.5	39
13	Spitz melanoma is a distinct subset of spitzoid melanoma. Modern Pathology, 2020, 33, 1122-1134.	2.9	67
14	The genomic landscapes of individual melanocytes from human skin. Nature, 2020, 586, 600-605.	13.7	79
15	Eruptive Spitz nevus, a striking example of benign metastasis. Scientific Reports, 2020, 10, 16216.	1.6	13
16	Pervasive chromosomal instability and karyotype order in tumour evolution. Nature, 2020, 587, 126-132.	13.7	221
17	769P APOBEC signatures and high tumour mutational burden as predictors of clinical outcomes and response to therapy in patients with urothelial carcinoma. Annals of Oncology, 2020, 31, S593.	0.6	1
18	The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. Archives of Pathology and Laboratory Medicine, 2020, 144, 500-522.	1.2	239

#	Article	IF	Citations
19	The Tumor Suppressor BAP1 Regulates the Hippo Pathway in Pancreatic Ductal Adenocarcinoma. Cancer Research, 2020, 80, 1656-1668.	0.4	18
20	The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathology, 2019, 29, 85-96.	2.1	88
21	Ocular Melanoma. , 2019, , 453-468.		0
22	Spitz Tumors. , 2019, , 395-410.		0
23	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 2019, 10, 3163.	5.8	205
24	The genetic evolution of metastatic uveal melanoma. Nature Genetics, 2019, 51, 1123-1130.	9.4	148
25	Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses. Cell Reports, 2019, 29, 573-588.e7.	2.9	62
26	Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma. Nature Communications, 2019, 10, 353.	5.8	99
27	Targeted Genomic Profiling of Acral Melanoma. Journal of the National Cancer Institute, 2019, 111, 1068-1077.	3.0	118
28	Next-Generation Sequencing of Uveal Melanoma for Detection of Genetic Alterations Predicting Metastasis. Translational Vision Science and Technology, 2019, 8, 18.	1.1	44
29	Association of Indoor Tanning Exposure With Age at Melanoma Diagnosis and BRAF V600E Mutations. Journal of the National Cancer Institute, 2019, 111, 1228-1231.	3.0	4
30	Ewing sarcoma in a child with neurofibromatosis type 1. Journal of Physical Education and Sports Management, 2019, 5, a004580.	0.5	0
31	Filigree-like Rete Ridges, Lobulated Nests, Rosette-like Structures, and Exaggerated Maturation Characterize Spitz Tumors With NTRK1 Fusion. American Journal of Surgical Pathology, 2019, 43, 737-746.	2.1	55
32	Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42. Modern Pathology, 2019, 32, 88-99.	2.9	76
33	The tumor suppressor <scp>BAP</scp>1 cooperates with <scp>BRAFV</scp>600E to promote tumor formation in cutaneous melanoma. Pigment Cell and Melanoma Research, 2019, 32, 269-279.	1.5	9
34	The genetic landscape of gliomas arising after therapeutic radiation. Acta Neuropathologica, 2019, 137, 139-150.	3.9	57
35	PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 778-783.	2.3	6
36	A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. Nature Communications, 2018, 9, 810.	5.8	56

#	Article	IF	Citations
37	Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway. Acta Neuropathologica, 2018, 135, 485-488.	3.9	54
38	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathologica, 2018, 135, 635-638.	3.9	17
39	Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Modern Pathology, 2018, 31, 660-673.	2.9	76
40	Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts. Acta Neuropathologica Communications, 2018, 6, 95.	2.4	13
41	Human tumor genomics and zebrafish modeling identify <i>SPRED1</i> loss as a driver of mucosal melanoma. Science, 2018, 362, 1055-1060.	6.0	123
42	Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation. Cancer Cell, 2018, 34, 56-68.e9.	7.7	113
43	Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution. Cancer Cell, 2018, 34, 45-55.e4.	7.7	157
44	Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile. Acta Neuropathologica, 2018, 136, 339-343.	3.9	37
45	The genetic landscape of ganglioglioma. Acta Neuropathologica Communications, 2018, 6, 47.	2.4	130
46	Spitz Tumors. , 2018, , 1-16.		0
47	Ocular Melanoma. , 2018, , 1-16.		0
48	Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro-Oncology, 2017, 19, now254.	0.6	155
49	RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. Cancer Cell, 2017, 31, 685-696.e6.	7.7	113
50	Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Annals of Oncology, 2017, 28, 1380-1387.	0.6	134
51	Multiple Merkel cell carcinomas: Late metastasis or multiple primary tumors? A molecular study. JAAD Case Reports, 2017, 3, 131-134.	0.4	6
52	Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Scientific Reports, 2017, 7, 44206.	1.6	28
53	Combined activation of MAP kinase pathway and Î²-catenin signaling cause deep penetrating nevi. Nature Communications, 2017, 8, 644.	5.8	107
54	Mutations in the promoter of the telomerase gene <i>TERT</i> contribute to tumorigenesis by a two-step mechanism. Science, 2017, 357, 1416-1420.	6.0	224

#	Article	IF	Citations
55	Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?. Cancer Genetics, 2017, 216-217, 74-78.	0.2	3
56	Filling the gaps in the genomic catalogue of melanoma subtypes. Pigment Cell and Melanoma Research, 2017, 30, 508-509.	1.5	1
57	Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Modern Pathology, 2017, 30, 246-254.	2.9	95
58	CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Computational Biology, 2016, 12, e1004873.	1.5	1,260
59	From melanocytes to melanomas. Nature Reviews Cancer, 2016, 16, 345-358.	12.8	596
60	<scp>NTRK3</scp> kinase fusions in Spitz tumours. Journal of Pathology, 2016, 240, 282-290.	2.1	128
61	The state of melanoma: challenges and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 404-416.	1.5	77
62	Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation. Acta Neuropathologica, 2016, 132, 757-760.	3.9	32
63	Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Modern Pathology, 2016, 29, 1012-1027.	2.9	54
64	Inactivating<i>MUTYH</i>germline mutations in pediatric patients with high-grade midline gliomas. Neuro-Oncology, 2016, 18, 752-753.	0.6	20
65	The Genetic Evolution of Melanoma. New England Journal of Medicine, 2016, 374, 993-996.	13.9	26
66	Congenital uveal melanoma?. Survey of Ophthalmology, 2016, 61, 59-64.	1.7	10
67	Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell and Melanoma Research, 2015, 28, 135-147.	1.5	81
68	Clinical, Histopathologic, and Genomic Features of Spitz Tumors With ALK Fusions. American Journal of Surgical Pathology, 2015, 39, 581-591.	2.1	129
69	Clinical activity of the <scp>MEK</scp> inhibitor trametinib in metastatic melanoma containing <i><scp>BRAF</scp></i> kinase fusion. Pigment Cell and Melanoma Research, 2015, 28, 607-610.	1.5	70
70	Metastatic Melanoma in Association With a Giant Congenital Melanocytic Nevus in an Adult. American Journal of Dermatopathology, 2015, 37, 487-494.	0.3	22
71	Activating MET kinase rearrangements in melanoma and Spitz tumours. Nature Communications, 2015, 6, 7174.	5.8	139
72	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clinical Cancer Research, 2015, 21, 2289-2296.	3.2	128

#	Article	IF	Citations
73	Genomic Classification of Cutaneous Melanoma. Cell, 2015, 161, 1681-1696.	13.5	2,562
74	The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. British Journal of Cancer, 2015, 112, 1326-1331.	2.9	30
75	A caveolin-dependent and PI3K/AKT-independent role of PTEN in Î²-catenin transcriptional activity. Nature Communications, 2015, 6, 8093.	5.8	58
76	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nature Genetics, 2015, 47, 1194-1199.	9.4	221
77	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10995-11000.	3.3	146
78	The Genetic Evolution of Melanoma from Precursor Lesions. New England Journal of Medicine, 2015, 373, 1926-1936.	13.9	824
79	Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nature Communications, 2014, 5, 3116.	5.8	521
80	A Mouse Model Uncovers LKB1 as an UVB-Induced DNA Damage Sensor Mediating CDKN1A (p21WAF1/CIP1) Degradation. PLoS Genetics, 2014, 10, e1004721.	1.5	40
81	Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell and Melanoma Research, 2014, 27, 37-47.	1.5	112
82	Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene, 2014, 33, 4724-4734.	2.6	174
83	Regulatory network decoded from epigenomes of surface ectoderm-derived cell types. Nature Communications, 2014, 5, 5442.	5.8	25
84	Ambiguous Melanocytic Tumors With Loss of 3p21. American Journal of Surgical Pathology, 2014, 38, 1088-1095.	2.1	75
85	Melanoma BRAF Fusionsâ€"Letter. Clinical Cancer Research, 2014, 20, 6631-6631.	3.2	8
86	Fluorescence In Situ Hybridization as an Ancillary Tool in the Diagnosis of Ambiguous Melanocytic Neoplasms. American Journal of Surgical Pathology, 2014, 38, 824-831.	2.1	70
87	The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia. Annual Review of Pathology: Mechanisms of Disease, 2014, 9, 239-271.	9.6	392
88	Alleleâ€specific imbalance mapping identifies <i>HDAC9</i> as a candidate gene for cutaneous squamous cell carcinoma. International Journal of Cancer, 2014, 134, 244-248.	2.3	14
89	Chromosomal Copy Number Analysis in Melanoma Diagnostics. Methods in Molecular Biology, 2014, 1102, 199-226.	0.4	16
90	In melanoma, <scp>H</scp>ippo signaling is affected by copy number alterations and <scp>YAP</scp>1 overexpression impairs patient survival. Pigment Cell and Melanoma Research, 2014, 27, 671-673.	1.5	28

#	Article	IF	Citations
91	Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP. Cancer Cell, 2014, 25, 822-830.	7.7	391
92	MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13845-13850.	3.3	29
93	Clonal BRAF Mutations in Melanocytic Nevi and Initiating Role of BRAF in Melanocytic Neoplasia. Journal of the National Cancer Institute, 2013, 105, 917-919.	3.0	92
94	SOX10 Ablation Arrests Cell Cycle, Induces Senescence, and Suppresses Melanomagenesis. Cancer Research, 2013, 73, 5709-5718.	0.4	70
95	Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells. Cancer Cell, 2013, 23, 811-825.	7.7	553
96	Targeting Activated KIT Signaling for Melanoma Therapy. Journal of Clinical Oncology, 2013, 31, 3288-3290.	0.8	16
97	Recurrent <scp>BRAF</scp> kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell and Melanoma Research, 2013, 26, 845-851.	1.5	114
98	Molecular Pathology of Cutaneous Melanoma and Nonmelanoma Skin Cancer. , 2013, , 269-306.		0
99	A Distinct Subset of Atypical Spitz Tumors is Characterized by BRAF Mutation and Loss of BAP1 Expression. American Journal of Surgical Pathology, 2012, 36, 818-830.	2.1	264
100	Raising the bar for melanoma cancer gene discovery. Pigment Cell and Melanoma Research, 2012, 25, 708-709.	1.5	3
101	Sunitinib Therapy for Melanoma Patients with <i>KIT</i> Mutations. Clinical Cancer Research, 2012, 18, 1457-1463.	3.2	197
102	Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene, 2012, 31, 1649-1660.	2.6	46
103	GNA11 (guanine nucleotide binding protein (G protein), alpha 11 (Gq class)). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2012, , .	0.1	0
104	GNAQ (guanine nucleotide binding protein (G protein), q polypeptide). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2012, , .	0.1	0
105	An unconventional deep penetrating melanocytic nevus with microscopic involvement of regional lymph nodes. Journal of Cutaneous Pathology, 2012, 39, 25-28.	0.7	20
106	GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta Neuropathologica, 2012, 123, 457-459.	3.9	60
107	Melanocytic nevi. , 2012, , 1150-1220.		1
108	Germline mutations in BAP1 predispose to melanocytic tumors. Nature Genetics, 2011, 43, 1018-1021.	9.4	662

#	Article	IF	Citations
109	<i>BRAF</i> mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell and Melanoma Research, 2011, 24, 345-351.	1.5	180
110	The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell and Melanoma Research, 2011, 24, 879-897.	1.5	225
111	Metastatic Melanoma With Striking Adenocarcinomatous Differentiation Illustrating Phenotypic Plasticity in Melanoma. American Journal of Surgical Pathology, 2011, 35, 1413-1418.	2.1	25
112	Assessment of Copy Number Status of Chromosomes 6 and 11 by FISH Provides Independent Prognostic Information in Primary Melanoma. American Journal of Surgical Pathology, 2011, 35, 1146-1150.	2.1	60
113	Genetic alterations in uveal melanoma. Expert Review of Ophthalmology, 2011, 6, 129-132.	0.3	0
114	Nodular lesions arising in a large congenital melanocytic naevus in a newborn with eruptive disseminated Spitz naevi. British Journal of Dermatology, 2011, 165, 1138-1142.	1.4	26
115	Molecular-Microscopical Correlation in Dermatopathology. Journal of Cutaneous Pathology, 2011, 38, 324-326.	0.7	12
116	An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second â€˜primaryâ€™ tumor. Journal of Cutaneous Pathology, 2011, 38, no-no.	0.7	15
117	KIT as a Therapeutic Target in Metastatic Melanoma. JAMA - Journal of the American Medical Association, 2011, 305, 2327.	3.8	755
118	Progress in the delivery of siRNA therapeutics: Potential in uveal melanoma. Drugs of the Future, 2011, 36, 229.	0.0	5
119	Use of Fluorescence In situ Hybridization (FISH) to Distinguish Intranodal Nevus From Metastatic Melanoma. American Journal of Surgical Pathology, 2010, 34, 231-237.	2.1	86
120	Mutation-driven drug development in melanoma. Current Opinion in Oncology, 2010, 22, 178-183.	1.1	94
121	Molecular Analysis of a Case of Nevus of Ota Showing Progressive Evolution to Melanoma With Intermediate Stages Resembling Cellular Blue Nevus. American Journal of Dermatopathology, 2010, 32, 301-305.	0.3	59
122	KIT as a Therapeutic Target in Melanoma. Journal of Investigative Dermatology, 2010, 130, 20-27.	0.3	99
123	Germline Variation Controls the Architecture of Somatic Alterations in Tumors. PLoS Genetics, 2010, 6, e1001136.	1.5	35
124	Beyond BRAF in Melanoma. Current Topics in Microbiology and Immunology, 2010, 355, 99-117.	0.7	14
125	Comment on â€œCutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KITâ€. Journal of Investigative Dermatology, 2010, 130, 2330-2331.	0.3	1
126	Loss of the p53/p63 Regulated Desmosomal Protein Perp Promotes Tumorigenesis. PLoS Genetics, 2010, 6, e1001168.	1.5	63

#	Article	IF	Citations
127	Somatic Mutation of Epidermal Growth Factor Receptor in a Small Subset of Cutaneous Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2010, 130, 901-903.	0.3	26
128	Mutations in<i>GNA11</i>in Uveal Melanoma. New England Journal of Medicine, 2010, 363, 2191-2199.	13.9	1,312
129	Genetic and morphologic features for melanoma classification. Pigment Cell and Melanoma Research, 2010, 23, 763-770.	1.5	130
130	Elevated Cutaneous Smad Activation Associates with Enhanced Skin Tumor Susceptibility in Organ Transplant Recipients. Clinical Cancer Research, 2009, 15, 5101-5107.	3.2	12
131	Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma. Molecular Cancer Research, 2009, 7, 41-54.	1.5	112
132	The Presence of Polyomavirus in Non-Melanoma Skin Cancer in Organ Transplant Recipients Is Rare. Journal of Investigative Dermatology, 2009, 129, 250-252.	0.3	54
133	Absence of Somatic Mutations of NEMO in Keratoacanthoma. Journal of Investigative Dermatology, 2009, 129, 2518-2520.	0.3	0
134	Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature, 2009, 457, 599-602.	13.7	1,433
135	Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. British Journal of Cancer, 2009, 101, 813-815.	2.9	139
136	Germline variation of the melanocortinâ€1 receptor does not explain shared risk for melanoma and thyroid cancer. Experimental Dermatology, 2009, 18, 548-552.	1.4	4
137	Frequent mutations in the MITF pathway in melanoma. Pigment Cell and Melanoma Research, 2009, 22, 435-444.	1.5	132
138	Genomeâ€wide associations studies for melanoma and nevi. Pigment Cell and Melanoma Research, 2009, 22, 527-528.	1.5	25
139	Fluorescence In Situ Hybridization (FISH) as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma. American Journal of Surgical Pathology, 2009, 33, 1146-1156.	2.1	441
140	Distribution and Significance of Occult Intraepidermal Tumor Cells Surrounding Primary Melanoma. Journal of Investigative Dermatology, 2008, 128, 2024-2030.	0.3	91
141	MC1R Variants Increase Risk of Melanomas Harboring BRAF Mutations. Journal of Investigative Dermatology, 2008, 128, 2485-2490.	0.3	78
142	Absence of PDGFRA Mutations in Primary Melanoma. Journal of Investigative Dermatology, 2008, 128, 488-489.	0.3	16
143	Doseâ€dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell and Melanoma Research, 2008, 21, 492-493.	1.5	213
144	Expanding the genetic spectrum of pigmentation. Pigment Cell and Melanoma Research, 2008, 21, 507-508.	1.5	4

#	Article	IF	Citations
145	Lack of somatic alterations of <i>MC1R</i> in primary melanoma. Pigment Cell and Melanoma Research, 2008, 21, 579-582.	1.5	8
146	Frequent p16-Independent Inactivation of p14ARF in Human Melanoma. Journal of the National Cancer Institute, 2008, 100, 784-795.	3.0	94
147	Improving Melanoma Classification by Integrating Genetic and Morphologic Features. PLoS Medicine, 2008, 5, e120.	3.9	322
148	Î²-Catenin induces immortalization of melanocytes by suppressing <i>p16^{INK4a}</i> expression and cooperates with N-Ras in melanoma development. Genes and Development, 2007, 21, 2923-2935.	2.7	283
149	The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer. Annals of Surgery, 2007, 246, 466-471.	2.1	407
150	Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach. Genes Chromosomes and Cancer, 2007, 46, 37-44.	1.5	89
151	Congenital Melanocytic Nevi Frequently Harbor NRAS Mutations but no BRAF Mutations. Journal of Investigative Dermatology, 2007, 127, 179-182.	0.3	302
152	Constitutive activation of the phosphatidyl inositol 3 kinase signalling pathway in acral lentiginous melanoma. British Journal of Dermatology, 2007, 158, 071115063928004-???.	1.4	17
153	Establishment of a novel melanoma cell line SMYM-PRGP showing cytogenetic and biological characteristics of the radial growth phase of acral melanomas. Cancer Science, 2007, 98, 958-963.	1.7	13
154	MC1R Germline Variants Confer Risk for BRAF-Mutant Melanoma. Science, 2006, 313, 521-522.	6.0	318
155	Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatologic Therapy, 2006, 19, 40-49.	0.8	186
156	Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nature Cell Biology, 2006, 8, 1053-1063.	4.6	296
157	PI3-Kinase Subunits Are Infrequent Somatic Targets in Melanoma. Journal of Investigative Dermatology, 2006, 126, 1660-1663.	0.3	59
158	In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling. Cancer Research, 2006, 66, 9483-9491.	0.4	271
159	Somatic Activation of KIT in Distinct Subtypes of Melanoma. Journal of Clinical Oncology, 2006, 24, 4340-4346.	0.8	1,481
160	Genetic Progression From Melanocyte to Malignant Melanoma. , 2006, , 197-209.		0
161	Genomic Analysis of Blue Nevi and Related Dermal Melanocytic Proliferations. American Journal of Surgical Pathology, 2005, 29, 1214-1220.	2.1	92
162	Distinct Sets of Genetic Alterations in Melanoma. New England Journal of Medicine, 2005, 353, 2135-2147.	13.9	2,501

#	Article	IF	Citations
163	Genomic Analysis of Melanocytic Neoplasia. Advances in Dermatology, 2005, 21, 81-99.	2.0	12
164	Molecular genetics of melanocytic neoplasia: practical applications for diagnosis. Pathology, 2004, 36, 458-461.	0.3	26
165	Mechanisms of Cell-Cycle Arrest in Spitz Nevi with Constitutive Activation of the MAP-Kinase Pathway. American Journal of Pathology, 2004, 164, 1783-1787.	1.9	99
166	Consumption of the Epidermis. American Journal of Surgical Pathology, 2004, 28, 1621-1625.	2.1	69
167	Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene, 2003, 22, 3081-3086.	2.6	123
168	Classifying Melanocytic Tumors Based on DNA Copy Number Changes. American Journal of Pathology, 2003, 163, 1765-1770.	1.9	448
169	Atypical junctional melanocytic proliferations in benign lichenoid keratosis. Human Pathology, 2003, 34, 706-709.	1.1	33
170	Two cases of unusual acral melanocytic tumors: Illustration of molecular cytogenetics as a diagnostic tool. Human Pathology, 2003, 34, 89-92.	1.1	26
171	Determinants of BRAF Mutations in Primary Melanomas. Journal of the National Cancer Institute, 2003, 95, 1878-1890.	3.0	604
172	The Longer Your Telomeres, the Larger Your Nevus?. American Journal of Dermatopathology, 2003, 25, 83-84.	0.3	13
173	Hypothesis: A Role for Telomere Crisis in Spontaneous Regression of Melanoma. Archives of Dermatology, 2003, 139, 667-8.	1.7	30
174	The longer your telomeres, the larger your nevus?. American Journal of Dermatopathology, 2003, 25, 83-4.	0.3	7
175	A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. Human Molecular Genetics, 2002, 11, 3221-3229.	1.4	129
176	Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1455-1460.	3.3	134
177	Persistent (Recurrent) Spitz Nevi. American Journal of Surgical Pathology, 2002, 26, 654-661.	2.1	117
178	Genetic Changes in Neoplasms Arising in Congenital Melanocytic Nevi. American Journal of Pathology, 2002, 161, 1163-1169.	1.9	228
179	Molecular Cytogenetics as a Diagnostic Tool for Typing Melanocytic Tumors. Recent Results in Cancer Research, 2002, 160, 92-99.	1.8	36
180	Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Research, 2002, 62, 3200-6.	0.4	217

#	Article	IF	Citations
181	Genomic Approaches to Skin Cancer Diagnosis. Archives of Dermatology, 2001, 137, 1507-11.	1.7	14
182	Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas. Molecular and Cellular Biology, 2001, 21, 2144-2153.	1.1	161
183	Mutations and Copy Number Increase of HRAS in Spitz Nevi with Distinctive Histopathological Features. American Journal of Pathology, 2000, 157, 967-972.	1.9	446
184	Molecular Cytogenetic Analysis of Spitz Nevi Shows Clear Differences to Melanoma. Journal of Investigative Dermatology, 1999, 113, 1065-1069.	0.3	316
185	A lymphohistiocytic variant of anaplastic large cell lymphoma with demonstration of the t(2;5)(p23;q35) chromosome translocation. British Journal of Haematology, 1998, 100, 187-190.	1.2	10
186	Chromosomal gains and losses in primary cutaneous melanomas detected by compartive genomic hybridization. Journal of Dermatological Science, 1998, 16, S142.	1.0	19
187	<title>Interactive system for registering adjacent tissue sections</title>. , 1998, 3260, 154.		1
188	Primary Cutaneous Natural Killer/ T-Cell Lymphoma. Archives of Dermatology, 1998, 134, 109-111.	1.7	27
189	Adult Rhabdomyoma of the Lip. American Journal of Dermatopathology, 1998, 20, 61-64.	0.3	17
190	Eosinophilic Globules in Spitz Nevi: No Evidence for Apoptosis. American Journal of Dermatopathology, 1998, 20, 551-554.	0.3	25
191	Elevated serum levels of soluble CD30 are associated with atopic dermatitis, but not with respiratory atopic disorders and allergic contact dermatitis. British Journal of Dermatology, 1997, 137, 185-187.	1.4	29
192	Elevated levels of interleukin-8 in blister fluid of bullous pemphigoidcompared with suction blisters of healthy control subjects. Journal of the American Academy of Dermatology, 1996, 34, 310-312.	0.6	42
193	Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Archives of Dermatological Research, 1996, 288, 353-357.	1.1	85
194	Phospholipase A2 is secreted by murine keratinocytes after stimulation with IL-1Î± and TNF-Î±. Archives of Dermatological Research, 1996, 288, 147-152.	1.1	9
195	Interleukin-10 production in malignant melanoma: Preferential detection of IL-10-secreting tumor cells in metastatic lesions. , 1996, 66, 607-610.		96
196	Melanoma in childhood: An EORTC-MCG multicenter study on the clinico-pathological aspects. , 1996, 68, 317-324.		94
197	Phospholipase A 2 is secreted by murine keratinocytes after stimulation with IL-1Î± and TNF-Î±. Archives of Dermatological Research, 1996, 288, 147-152.	1.1	1
198	Primary Neuroendocrine Carcinoma of the Skin with an Unusual Follicular Lymphocytic Infiltrate of the Dermis. American Journal of Dermatopathology, 1996, 18, 625-628.	0.3	15

#	Article	IF	Citations
199	Autoantibodies to annexins: a diagnostic marker for cutaneous disorders?. Journal of Dermatological Science, 1994, 8, 194-202.	1.0	17
200	Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patients. Cancer, 1993, 72, 741-749.	2.0	99
201	Localization of annexins in normal and diseased human skin. Journal of Dermatological Science, 1993, 6, 225-234.	1.0	25